Browsing by Subject "NCAPG2"
Now showing 1 - 1 of 1
Results Per Page
Sort Options
- PublicationOpen AccessmiR-638 suppresses cervical cancer progression by inhibiting NCAPG2 under the treatment of Tetrandrine(Universidad de Murcia, Departamento de Biologia Celular e Histiologia, 2024) Wang, Min; Liu, Kai; Zhou, Zhongming; Geng, HuizhuanBackground. The interaction of microRNA with Chinese herbal medicines is a promising therapeutic approach for prevention of cervical cancer. Methods. Western blotting or qRT-PCR were carried out to identify the expression of NCAPG2 and miR-638. A tetrandrine (TET) cell model was used to explore the effects of miR-638 and its target gene NCAPG2 using CCK-8, transwell, wound healing, and western blot assays. Furthermore, luciferase activity assay was conducted to measure the interaction among TET, NCAPG2 and miR-638. Results. Under TET treatment, Hela and SiHa cells exhibited repressed cell viability, migration, invasion, and epithelial-mesenchymal transition (EMT), and these effects were further enhanced by high expression of miR-638. In contrast, NCAPG2 expression was low in TET-treated cells and had an opposite effect to that of miR-638. Conclusion. We highlighted that miR-638 suppresses cervical cancer progression by inhibiting NCAPG2 under tetrandrine treatment